SenesTech
Founded Year
2002Stage
IPO | IPODate of IPO
12/9/2016Market Cap
0.00BStock Price
0.45About SenesTech
SenesTech is a biotech company engaged in reproductive physiology. Its aims to develop nonsurgical methods for controlling reproduction in rodent and wildlife populations methods that could per the company profoundly increase food production throughout the world. SenesTech is currently using its chemical compound branded ContraPest to control the Southeast Asian Rice Rat and increase rice production. The first technology of its kind, ContraPest uses species-specific protocols to accelerate the natural depletion of follicles in the mammalian ovary, causing sterility. Follicles are depleted without causing systemic toxicity, adverse side effects, or environmental impacts. Based on technology licensed from the University of Arizona, SenesTech was founded in Flagstaff in 2002. The company recently entered into a strategic alliance with the government of Australia to control rodent populations in Australia, New Zealand, and Southeast Asia. Domestic and international patents are pending.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
SenesTech Patents
SenesTech has filed 4 patents.
The 3 most popular patent topics include:
- Dicarboxylic acids
- Epoxides
- Human female endocrine system
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/19/2018 | 7/5/2022 | Pumps, Toilets, Sanitation, Woodworking, Waste | Grant |
Application Date | 6/19/2018 |
|---|---|
Grant Date | 7/5/2022 |
Title | |
Related Topics | Pumps, Toilets, Sanitation, Woodworking, Waste |
Status | Grant |
Latest SenesTech News
Sep 11, 2023
News provided by Share this article Share toX PHOENIX, Sept. 11, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES , "SenesTech" or the "Company"), ( www.senestech.com ) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced that ContraPest is being deployed into a new vertical, waste water treatment facilities, with deployments in both Washington and California. Waste water management presents a unique challenge in controlling rat infestations. Poisons can not be introduced into the water supply, and ground-based stations may not be appropriate for much of the facilities. As a result, at the Washington facility, a local pest control company will be using both bait stations and ElevateTM stations at a widespread facility to manage and ensure rat activity at the site is kept to a minimum, including in subterranean treatment tunnels and pump stations. At the California facility, above ground Elevate stations are being used exclusively due to the facility's design and the pattern of the rat infestation. "Municipalities and government entities comprise a broad and diverse customer base. We are continuously working with these customers, and the pest management professionals who service them, to understand their specific needs and to guide them as to how best to add ContraPest to their integrated pest management system. Waste water treatment deployment has very specific challenges, and we are able to develop and share deployment protocols utilized by other, similar customers," said Joel Fruendt, SenesTech's President and Chief Executive Officer. About SenesTech We are the experts in rat fertility control. Our passion is to create a healthy environment by better controlling rat pest populations. We keep an inescapable truth in mind. Two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. We invented ContraPest, the only U.S. EPA registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. We strive for clean cities, efficient businesses, and happy households – with a product that was designed to be effective and sustainable without killing rats. At SenesTech, we are committed to improving the health of the world by humanely managing animal populations through fertility control. For more information visit https://senestech.com/ and https://contrapeststore.com . CONTACT:
SenesTech Frequently Asked Questions (FAQ)
When was SenesTech founded?
SenesTech was founded in 2002.
Where is SenesTech's headquarters?
SenesTech's headquarters is located at 2225 East Gemini Drive, Flagstaff.
What is SenesTech's latest funding round?
SenesTech's latest funding round is IPO.
Who are the investors of SenesTech?
Investors of SenesTech include University of Arizona and Northern Arizona Center for Emerging Technologies.
Who are SenesTech's competitors?
Competitors of SenesTech include Biolog, Intralytix, Unima, GangaGen, Bloomage BioTech and 13 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare SenesTech to Competitors
Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.
Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.
bcs Biotech SpA is a biotech company based in Cagliari, Italy. The activities of BCS Biotech have focused on the design and production of PCR kits for the medical, veterinary and food processing markets. The years of start-up and research have led to the development of products and efficient quality-oriented manufacturing facilities. Recently, BCS has introduced a diagnostic system on microchips.nMEDICA 2008n
Intralytix is a biotechnology company focused on the discovery, production, and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Sunzen Biotech Berhad ("Sunzen Biotech"‚) is an animal health specialist, focused on developing, manufacturing and marketing animal health care products. The company market a range of animal health products which includes feed additives, nutritional feed supplements, veterinary pharmaceuticals, animal vaccines and other animal health care products for livestock such as poultry, swine, goats and cattle, as well as companion animals. The company develop and manufacture non-antibiotic animal health products that comply with international safety standards to ensure public safety. And in recognition of the company's focused Research and Development in non-antibiotic animal biotechnology, Sunzen Biotech has been accorded BioNexus Status, which entitles Sunzen to tax incentives and other privileges specified under the Bionexus bill of guarantees, from the Malaysian Biotechnology Corporation. Sunzen is also the sole distributor for Pfizer Animal Health products in Malaysia, Singapore, andnBrunei. The company are proud to say that today "Sunzen"‚ products are supplied to feed millers and livestock producers in Malaysia and across the region.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
